Publications by authors named "S Margarita"
Background: Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems. The specific criteria for diagnosing MetS vary among different medical organizations but are typically based on the evaluation of abdominal obesity, high blood pressure, hyperglycemia, and dyslipidemia. A unique, quantitative and independent estimation of the risk of MetS based only on quantitative biomarkers is highly desirable for the comparison between patients and to study the individual progression of the disease in a quantitative manner.
View Article and Find Full Text PDFPrevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD.
Clin Gastroenterol Hepatol
November 2024
Article Synopsis
- This study investigates the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) and advanced fibrosis among relatives of patients with advanced MASLD, highlighting the condition's genetic aspects.
- Results showed that 56.8% of relatives had MASLD, with 14.4% presenting advanced fibrosis, indicating a significant risk, especially linked to factors like body mass index and diabetes.
- Despite some genetic risk variants being more common among affected individuals, they did not effectively enhance the screening process for advanced fibrosis in relatives, underscoring the need for family screening based on clinical guidelines.
Predictors of controlled attenuation parameter in metabolic dysfunction.
United European Gastroenterol J
April 2024
Background & Aims: Hepatic fat content can be non-invasively estimated by controlled attenuation parameter (CAP) during transient elastography. The aim of this study was to examine the determinants and predictors of CAP values in individuals with metabolic dysfunction.
Methods: We enrolled 1230 consecutive apparently healthy individuals (Liver-Bible-2022 cohort) with ≥3 metabolic dysfunction features.
Article Synopsis
- Fatty liver disease, often linked to metabolic dysfunction (MAFLD), increases cardiovascular disease risk and is associated with higher levels of the cytokine IL32, which is tied to lipotoxicity.
- This study analyzed the levels of IL32 in 948 individuals with metabolic dysfunction to explore its connection with blood pressure control.
- Findings revealed that higher IL32 levels were independently linked to increased systolic blood pressure and worse blood pressure management, regardless of other demographic or treatment factors.
Background: The PNPLA3 p.I148M variant is the main genetic determinant of nonalcoholic fatty liver disease, and PNPLA3 silencing is being evaluated to treat this liver condition. Data suggest that the p.
View Article and Find Full Text PDF